Which has stronger earnings and valuation, GERN or ALKS?

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Geron $183.88M 4.46 -$83.50M -$0.11 N/A Alkermes $1.48B 5.53 $241.66M $0.90 54.01

Is GERN or ALKS more profitable?

Alkermes has a net margin of 3.96% compared to Geron's net margin of -35.48%. Alkermes' return on equity of 4.15% beat Geron's return on equity. Company Net Margins Return on Equity Return on Assets Geron -35.48% -23.31% -10.08% Alkermes 3.96% 4.15% 2.19%

Does the media prefer GERN or ALKS?

In the previous week, Alkermes had 28 more articles in the media than Geron. MarketBeat recorded 32 mentions for Alkermes and 4 mentions for Geron. Geron's average media sentiment score of 1.21 beat Alkermes' score of 1.12 indicating that Geron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 16 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, GERN or CLDX?

Geron has higher revenue and earnings than Celldex Therapeutics. Geron is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Geron $183.88M 4.46 -$83.50M -$0.11 N/A Celldex Therapeutics $865K 3,395.57 -$258.76M -$4.26 N/A

Does the media refer more to GERN or CLDX?

In the previous week, Celldex Therapeutics had 13 more articles in the media than Geron. MarketBeat recorded 17 mentions for Celldex Therapeutics and 4 mentions for Geron. Geron's average media sentiment score of 1.21 beat Celldex Therapeutics' score of 0.74 indicating that Geron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BCRX or GERN?

In the previous week, BioCryst Pharmaceuticals had 6 more articles in the media than Geron. MarketBeat recorded 10 mentions for BioCryst Pharmaceuticals and 4 mentions for Geron. Geron's average media sentiment score of 1.21 beat BioCryst Pharmaceuticals' score of 1.13 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, GERN or ZBIO?

Geron has higher revenue and earnings than Zenas BioPharma. Geron is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Geron $183.88M 4.46 -$83.50M -$0.11 N/A Zenas BioPharma $10M 199.10 -$377.74M -$8.47 N/A

Is GERN or ZBIO more profitable?

Zenas BioPharma has a net margin of 0.00% compared to Geron's net margin of -35.48%. Geron's return on equity of -23.31% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Geron -35.48% -23.31% -10.08% Zenas BioPharma N/A -99.99% -58.06%

Does the media refer more to GERN or ZBIO?

In the previous week, Zenas BioPharma had 1 more articles in the media than Geron. MarketBeat recorded 5 mentions for Zenas BioPharma and 4 mentions for Geron. Zenas BioPharma's average media sentiment score of 1.24 beat Geron's score of 1.21 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, INVA or GERN?

Innoviva has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $420.69M 3.69 $271.17M $6.01 3.50 Geron $183.88M 4.46 -$83.50M -$0.11 N/A

Is INVA or GERN more profitable?

Innoviva has a net margin of 119.89% compared to Geron's net margin of -35.48%. Innoviva's return on equity of 33.33% beat Geron's return on equity. Company Net Margins Return on Equity Return on Assets Innoviva 119.89% 33.33% 22.67% Geron -35.48% -23.31% -10.08%

Does the media prefer INVA or GERN?

In the previous week, Innoviva had 4 more articles in the media than Geron. MarketBeat recorded 8 mentions for Innoviva and 4 mentions for Geron. Innoviva's average media sentiment score of 1.45 beat Geron's score of 1.21 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Geron (GERN) Competitors

$1.28 -0.06 (-4.70%)

As of 11:45 AM Eastern

Compare

GERN vs. ALKS, CLDX, BCRX, ZBIO, and INVA

Should you buy Geron stock or one of its competitors? MarketBeat compares Geron with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Geron include Alkermes (ALKS), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Zenas BioPharma (ZBIO), and Innoviva (INVA). These companies are all part of the "biotechnology" industry.

How does Geron compare to Alkermes?

Geron (NASDAQ:GERN) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

73.7% of Geron shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 1.7% of Geron shares are owned by insiders. Comparatively, 4.6% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.46	-$83.50M	-$0.11	N/A
Alkermes	$1.48B	5.53	$241.66M	$0.90	54.01

Geron currently has a consensus price target of $4.00, suggesting a potential upside of 213.23%. Alkermes has a consensus price target of $54.56, suggesting a potential upside of 12.25%. Given Geron's higher probable upside, analysts clearly believe Geron is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Geron has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

In the previous week, Alkermes had 28 more articles in the media than Geron. MarketBeat recorded 32 mentions for Alkermes and 4 mentions for Geron. Geron's average media sentiment score of 1.21 beat Alkermes' score of 1.12 indicating that Geron is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	16 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes has a net margin of 3.96% compared to Geron's net margin of -35.48%. Alkermes' return on equity of 4.15% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
Alkermes	3.96%	4.15%	2.19%

Summary

Alkermes beats Geron on 14 of the 17 factors compared between the two stocks.

How does Geron compare to Celldex Therapeutics?

Geron (NASDAQ:GERN) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Celldex Therapeutics has a net margin of 0.00% compared to Geron's net margin of -35.48%. Geron's return on equity of -23.31% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Geron has higher revenue and earnings than Celldex Therapeutics. Geron is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.46	-$83.50M	-$0.11	N/A
Celldex Therapeutics	$865K	3,395.57	-$258.76M	-$4.26	N/A

Geron has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

73.7% of Geron shares are held by institutional investors. 1.7% of Geron shares are held by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Geron currently has a consensus target price of $4.00, suggesting a potential upside of 213.23%. Celldex Therapeutics has a consensus target price of $54.62, suggesting a potential upside of 45.95%. Given Geron's higher probable upside, research analysts clearly believe Geron is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Celldex Therapeutics had 13 more articles in the media than Geron. MarketBeat recorded 17 mentions for Celldex Therapeutics and 4 mentions for Geron. Geron's average media sentiment score of 1.21 beat Celldex Therapeutics' score of 0.74 indicating that Geron is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Celldex Therapeutics beats Geron on 9 of the 17 factors compared between the two stocks.

How does Geron compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Geron (NASDAQ:GERN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Geron has a net margin of -35.48% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Geron's return on equity of -23.31% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Geron	-35.48%	-23.31%	-10.08%

BioCryst Pharmaceuticals currently has a consensus target price of $20.80, suggesting a potential upside of 132.01%. Geron has a consensus target price of $4.00, suggesting a potential upside of 213.23%. Given Geron's higher possible upside, analysts plainly believe Geron is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

BioCryst Pharmaceuticals has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.60	$263.86M	-$1.78	N/A
Geron	$183.88M	4.46	-$83.50M	-$0.11	N/A

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 1.7% of Geron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BioCryst Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Geron has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

In the previous week, BioCryst Pharmaceuticals had 6 more articles in the media than Geron. MarketBeat recorded 10 mentions for BioCryst Pharmaceuticals and 4 mentions for Geron. Geron's average media sentiment score of 1.21 beat BioCryst Pharmaceuticals' score of 1.13 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioCryst Pharmaceuticals beats Geron on 9 of the 16 factors compared between the two stocks.

How does Geron compare to Zenas BioPharma?

Geron (NASDAQ:GERN) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Geron currently has a consensus price target of $4.00, indicating a potential upside of 213.23%. Zenas BioPharma has a consensus price target of $44.29, indicating a potential upside of 40.42%. Given Geron's higher possible upside, equities analysts plainly believe Geron is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Geron has higher revenue and earnings than Zenas BioPharma. Geron is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.46	-$83.50M	-$0.11	N/A
Zenas BioPharma	$10M	199.10	-$377.74M	-$8.47	N/A

In the previous week, Zenas BioPharma had 1 more articles in the media than Geron. MarketBeat recorded 5 mentions for Zenas BioPharma and 4 mentions for Geron. Zenas BioPharma's average media sentiment score of 1.24 beat Geron's score of 1.21 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Geron has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.96, meaning that its stock price is 196% less volatile than the broader market.

73.7% of Geron shares are held by institutional investors. 1.7% of Geron shares are held by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Zenas BioPharma has a net margin of 0.00% compared to Geron's net margin of -35.48%. Geron's return on equity of -23.31% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
Zenas BioPharma	N/A	-99.99%	-58.06%

Summary

Geron and Zenas BioPharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Geron compare to Innoviva?

Innoviva (NASDAQ:INVA) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Innoviva had 4 more articles in the media than Geron. MarketBeat recorded 8 mentions for Innoviva and 4 mentions for Geron. Innoviva's average media sentiment score of 1.45 beat Geron's score of 1.21 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$420.69M	3.69	$271.17M	$6.01	3.50
Geron	$183.88M	4.46	-$83.50M	-$0.11	N/A

Innoviva has a net margin of 119.89% compared to Geron's net margin of -35.48%. Innoviva's return on equity of 33.33% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Geron	-35.48%	-23.31%	-10.08%

Innoviva has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Geron has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 1.7% of Geron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Innoviva presently has a consensus price target of $36.20, indicating a potential upside of 72.24%. Geron has a consensus price target of $4.00, indicating a potential upside of 213.23%. Given Geron's higher possible upside, analysts plainly believe Geron is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Innoviva beats Geron on 13 of the 16 factors compared between the two stocks.

Get Geron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GERN vs. The Competition

Export

Metric	Geron	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$824.35M	$3.65B	$6.86B	$12.37B
Dividend Yield	N/A	2.13%	2.65%	10.11%
P/E Ratio	-11.68	23.06	27.45	23.66
Price / Sales	4.46	212.49	495.52	78.38
Price / Cash	N/A	165.25	51.74	58.30
Price / Book	3.65	7.92	9.91	5.85
Net Income	-$83.50M	$23.81M	$3.61B	$336.64M
7 Day Performance	-10.07%	-1.14%	-0.29%	0.02%
1 Month Performance	-0.23%	-7.49%	-3.96%	-5.24%
1 Year Performance	11.04%	39.62%	22.83%	17.56%

Geron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GERN Geron	2.5936 of 5 stars	$1.28 -4.7%	$4.00 +213.2%	+22.4%	$824.35M	$183.88M	N/A	70	Positive News Upcoming Earnings
ALKS Alkermes	3.0385 of 5 stars	$50.03 +3.5%	$54.56 +9.1%	+79.1%	$8.11B	$1.48B	131.66	2,050	Positive News Analyst Forecast
CLDX Celldex Therapeutics	2.8668 of 5 stars	$38.49 +2.6%	$54.62 +41.9%	+68.7%	$2.94B	$865K	N/A	150	Upcoming Earnings Analyst Forecast
BCRX BioCryst Pharmaceuticals	3.5837 of 5 stars	$9.24 -3.0%	$20.80 +125.1%	+12.4%	$2.42B	$874.84M	N/A	530	Positive News Upcoming Earnings Short Interest Decrease
ZBIO Zenas BioPharma	3.9237 of 5 stars	$32.27 +3.8%	$44.29 +37.2%	+104.9%	$1.96B	$10M	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GERN) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Geron (GERN) Competitors

GERN vs. ALKS, CLDX, BCRX, ZBIO, and INVA

How does Geron compare to Alkermes?

Summary

How does Geron compare to Celldex Therapeutics?

Summary

How does Geron compare to BioCryst Pharmaceuticals?

Summary

How does Geron compare to Zenas BioPharma?

Summary

How does Geron compare to Innoviva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GERN vs. The Competition

Geron Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Geron (GERN) Competitors

GERN vs. ALKS, CLDX, BCRX, ZBIO, and INVA

How does Geron compare to Alkermes?

Do institutionals and insiders hold more shares of GERN or ALKS?

Which has stronger earnings and valuation, GERN or ALKS?

Do analysts rate GERN or ALKS?

Which has more risk & volatility, GERN or ALKS?

Does the media prefer GERN or ALKS?

Is GERN or ALKS more profitable?

Summary

How does Geron compare to Celldex Therapeutics?

Is GERN or CLDX more profitable?

Which has better earnings & valuation, GERN or CLDX?

Which has more risk & volatility, GERN or CLDX?

Do institutionals & insiders hold more shares of GERN or CLDX?

Do analysts prefer GERN or CLDX?

Does the media refer more to GERN or CLDX?

Summary

How does Geron compare to BioCryst Pharmaceuticals?

Is BCRX or GERN more profitable?

Do analysts prefer BCRX or GERN?

Which has preferable earnings and valuation, BCRX or GERN?

Do insiders and institutionals hold more shares of BCRX or GERN?

Which has more volatility and risk, BCRX or GERN?

Does the media prefer BCRX or GERN?

Summary

How does Geron compare to Zenas BioPharma?

Do analysts recommend GERN or ZBIO?

Which has better earnings & valuation, GERN or ZBIO?

Does the media refer more to GERN or ZBIO?

Which has more volatility and risk, GERN or ZBIO?

Do institutionals and insiders have more ownership in GERN or ZBIO?

Is GERN or ZBIO more profitable?

Summary

How does Geron compare to Innoviva?

Does the media prefer INVA or GERN?

Which has stronger valuation and earnings, INVA or GERN?

Is INVA or GERN more profitable?

Which has more volatility and risk, INVA or GERN?

Do insiders and institutionals have more ownership in INVA or GERN?

Do analysts prefer INVA or GERN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GERN vs. The Competition

Geron Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools